| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
IC50: 8 nM (TNIK), 4.7 μM (hERG), 6.3 μM (β-lactamase)[1]
TINK-IN-1 targets TNIK (Traf2- and Nck-interacting kinase), a member of the MAP4K family. It is a selective and potent inhibitor with an IC50 of 8 nM. It also shows activity against hERG (IC50: 4.7 μM) and β-lactamase (IC50: 6.3 μM). It is involved in the MAPK/ERK and Wnt/β-catenin pathways. |
|---|---|
| ln Vitro |
In vitro, TINK-IN-1 inhibits colorectal cancer cell viability. It is a potent and selective TNIK inhibitor with an IC50 of 8 nM. It shows selectivity over hERG (IC50: 4.7 μM) and β-lactamase (IC50: 6.3 μM). The compound is used to study the role of TNIK in cancer and neurological disorders.
|
| ln Vivo |
In vivo, TINK-IN-1 can be used to study mental retardation. Its inhibition of colorectal cancer cell viability suggests potential for cancer therapy, but detailed in vivo efficacy data are limited. Animal studies would be needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
Cell-free assays for TINK-IN-1 involve TNIK kinase activity assays. The enzyme is incubated with ATP and a peptide substrate in the presence of varying concentrations of the compound. Kinase activity is measured using radioactive or fluorescence-based detection. IC50 values are calculated from dose-response curves. Selectivity profiling against other kinases is performed using panel screening.
|
| Cell Assay |
Cellular assays for TINK-IN-1 use colorectal cancer cell lines. Cells are treated with TINK-IN-1 at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT or CellTiter-Glo assays. TNIK signaling is assessed by Western blot for downstream targets. Apoptosis and cell cycle analysis are performed by flow cytometry.
|
| Animal Protocol |
In vivo animal studies for TINK-IN-1 have not been extensively reported. Based on its in vitro activity, xenograft mouse models of colorectal cancer could be used to evaluate efficacy. Animals would be administered TINK-IN-1 orally or intraperitoneally, and tumor growth would be monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of TINK-IN-1 are not extensively characterized. Storage: powder at -20°C for up to 3 years; in solvent at -80°C for 6 months or -20°C for 1 month. Solubility: soluble in DMSO. Molecular weight: 416.47.
|
| Toxicity/Toxicokinetics |
Toxicity of TINK-IN-1: hERG inhibition (IC50: 4.7 μM) suggests potential cardiotoxicity at high concentrations. Comprehensive toxicity data are limited. The compound is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
TINK-IN-1 is a research compound with potential applications in cancer and neurological research. It is a potent and selective TNIK inhibitor. The compound is available from chemical suppliers. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C24H24N4O3
|
|---|---|
| Molecular Weight |
416.472365379334
|
| Exact Mass |
416.184
|
| CAS # |
1417795-25-5
|
| PubChem CID |
71540729
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
605
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C(C=C1)C#N)C2=CC(=NC=C2)NC3=CC(=C(C=C3)N4CCOCC4)OC
|
| InChi Key |
JKDVQSBZXOTCNO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H24N4O3/c1-29-22-6-3-17(16-25)13-20(22)18-7-8-26-24(14-18)27-19-4-5-21(23(15-19)30-2)28-9-11-31-12-10-28/h3-8,13-15H,9-12H2,1-2H3,(H,26,27)
|
| Chemical Name |
4-methoxy-3-[2-(3-methoxy-4-morpholin-4-ylanilino)pyridin-4-yl]benzonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4011 mL | 12.0057 mL | 24.0113 mL | |
| 5 mM | 0.4802 mL | 2.4011 mL | 4.8023 mL | |
| 10 mM | 0.2401 mL | 1.2006 mL | 2.4011 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
